The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Online Program Home
Abstract Details
|
Activity Number:
|
572
|
|
Type:
|
Contributed
|
|
Date/Time:
|
Wednesday, August 1, 2012 : 2:00 PM to 3:50 PM
|
|
Sponsor:
|
Biopharmaceutical Section
|
| Abstract - #304891 |
|
Title:
|
New Era of HIV Drug Development in a Noninferiority Setting
|
|
Author(s):
|
Jing Zhao*+
|
|
Companies:
|
Merck Research Laboratories
|
|
Address:
|
UG1C-46, North Wales, PA, 19454-1099, United States
|
|
Keywords:
|
noninferiority ;
antiretroviral therapy ;
clinical trial
|
|
Abstract:
|
In 1982 HIV/AIDS caused panic across the world, changing the way many thought about disease and survival. Since then this disease has been spreading at an annual rate of 50 thousand new infections in USA and 2.7 million worldwide. At the end of last century the new combination drugs --- antiretroviral therapy(ART) were found to be highly effective in controlling the deadly disease. Ever since, more and more new developed ARTs have prolonged the lives of HIV patients and transformed HIV/AIDS from an acute disease to a chronic disease. However, there is still an unmet medical need for HIV infected patients to seek novel HIV therapies as more patients are failing current HIV regiments, developing resistance and complications to the drugs. This presentation discusses the new challenges and opportunity for the HIV drug development in the lieu of the current regulatory and economic environment, and also shares a real life experience from a Phase III clinical trial.
|
The address information is for the authors that have a + after their name.
Authors who are presenting talks have a * after their name.
Back to the full JSM 2012 program
|
2012 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.